World's Best Scientists 2026 revealed!

D-Index & Metrics

Microbiology

D-Index
56
Citations
14974
World Ranking
3668
National Ranking
1440

Tami Pilot-Matias publication distribution in Microbiology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Microbiology in 2026. The highlighted bar marks where Tami Pilot-Matias sits on this spectrum.

55–64 publications: 8 scientists 65–74 publications: 29 scientists 75–84 publications: 55 scientists 85–94 publications: 112 scientists 95–104 publications: 137 scientists 105–114 publications: 190 scientists 115–124 publications: 235 scientists 125–134 publications: 234 scientists 135–144 publications: 288 scientists 145–154 publications: 264 scientists 155–164 publications: 264 scientists 165–174 publications: 253 scientists 175–184 publications: 276 scientists 185–194 publications: 190 scientists 195–204 publications: 233 scientists 205–214 publications: 207 scientists 215–224 publications: 198 scientists 225–234 publications: 155 scientists 235–244 publications: 161 scientists 245–254 publications: 160 scientists 255–264 publications: 146 scientists 265–274 publications: 139 scientists 275–284 publications: 148 scientists 285–294 publications: 115 scientists 295–304 publications: 96 scientists 305–314 publications: 88 scientists 315–324 publications: 106 scientists 325–334 publications: 65 scientists 335–344 publications: 76 scientists 345–354 publications: 64 scientists 355–364 publications: 62 scientists 365–374 publications: 65 scientists 375–384 publications: 61 scientists 385–394 publications: 34 scientists 395–404 publications: 44 scientists 405–414 publications: 36 scientists 415–424 publications: 35 scientists 425–434 publications: 29 scientists 435–444 publications: 33 scientists 445–454 publications: 34 scientists 455–464 publications: 25 scientists 465–474 publications: 26 scientists 475–484 publications: 20 scientists 485–494 publications: 19 scientists 495–504 publications: 16 scientists 505–514 publications: 17 scientists 515–524 publications: 23 scientists 525–534 publications: 14 scientists 535–544 publications: 14 scientists 545–554 publications: 18 scientists 555–564 publications: 12 scientists 565–574 publications: 7 scientists 575–584 publications: 9 scientists 585–594 publications: 9 scientists 595–604 publications: 9 scientists 605–614 publications: 7 scientists 615–624 publications: 9 scientists 625–634 publications: 7 scientists 635–644 publications: 4 scientists 645–654 publications: 5 scientists 655–664 publications: 6 scientists 665–674 publications: 7 scientists 675–678 publications: 3 scientists 679+ publications: 99 scientists
55 publications 679+

This scientist: 145 publications — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 679 publications or more.

Tami Pilot-Matias D-index placement in Microbiology in 2026

The chart shows the D-index (discipline H-index) distribution of Microbiology scientists ranked by Research.com in 2026. The highlighted bar marks where Tami Pilot-Matias sits on this spectrum.

40 D-Index: 30 scientists 41 D-Index: 86 scientists 42 D-Index: 90 scientists 43 D-Index: 117 scientists 44 D-Index: 122 scientists 45 D-Index: 123 scientists 46 D-Index: 108 scientists 47 D-Index: 110 scientists 48 D-Index: 106 scientists 49 D-Index: 109 scientists 50 D-Index: 129 scientists 51 D-Index: 111 scientists 52 D-Index: 116 scientists 53 D-Index: 127 scientists 54 D-Index: 134 scientists 55 D-Index: 134 scientists 56 D-Index: 111 scientists 57 D-Index: 136 scientists 58 D-Index: 162 scientists 59 D-Index: 151 scientists 60 D-Index: 139 scientists 61 D-Index: 122 scientists 62 D-Index: 126 scientists 63 D-Index: 144 scientists 64 D-Index: 109 scientists 65 D-Index: 103 scientists 66 D-Index: 124 scientists 67 D-Index: 112 scientists 68 D-Index: 103 scientists 69 D-Index: 131 scientists 70 D-Index: 93 scientists 71 D-Index: 93 scientists 72 D-Index: 96 scientists 73 D-Index: 92 scientists 74 D-Index: 80 scientists 75 D-Index: 66 scientists 76 D-Index: 87 scientists 77 D-Index: 60 scientists 78 D-Index: 73 scientists 79 D-Index: 59 scientists 80 D-Index: 57 scientists 81 D-Index: 55 scientists 82 D-Index: 47 scientists 83 D-Index: 77 scientists 84 D-Index: 50 scientists 85 D-Index: 45 scientists 86 D-Index: 42 scientists 87 D-Index: 41 scientists 88 D-Index: 32 scientists 89 D-Index: 38 scientists 90 D-Index: 35 scientists 91 D-Index: 34 scientists 92 D-Index: 27 scientists 93 D-Index: 26 scientists 94 D-Index: 33 scientists 95 D-Index: 22 scientists 96 D-Index: 37 scientists 97 D-Index: 22 scientists 98 D-Index: 21 scientists 99 D-Index: 22 scientists 100 D-Index: 30 scientists 101 D-Index: 16 scientists 102 D-Index: 20 scientists 103 D-Index: 17 scientists 104 D-Index: 19 scientists 105 D-Index: 16 scientists 106 D-Index: 19 scientists 107 D-Index: 18 scientists 108 D-Index: 14 scientists 109 D-Index: 10 scientists 110 D-Index: 9 scientists 111 D-Index: 7 scientists 112 D-Index: 11 scientists 113 D-Index: 6 scientists 114 D-Index: 15 scientists 115 D-Index: 10 scientists 116 D-Index: 12 scientists 117 D-Index: 7 scientists 118 D-Index: 10 scientists 119 D-Index: 10 scientists 120 D-Index: 11 scientists 121 D-Index: 2 scientists 122 D-Index: 7 scientists 123 D-Index: 12 scientists 124 D-Index: 5 scientists 125 D-Index: 9 scientists 126 D-Index: 6 scientists 127+ D-Index: 95 scientists
40 D-Index 127+

This scientist: 56 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 127 D-Index or more.

Overview

Tami Pilot-Matias is affiliated with AbbVie in the United States and has a substantial body of research primarily within the field of Medicine. Their work notably spans across subfields such as Epidemiology, Hepatology, Infectious Diseases, Genetics, and Pediatrics, Perinatology, and Child Health.

Their research focuses on several key topics, including:

  • Hepatitis C virus research
  • Liver Disease Diagnosis and Treatment
  • Hepatitis B Virus Studies
  • Liver Disease and Transplantation
  • HIV/AIDS drug development and treatment
  • Liver Diseases and Immunity
  • Childhood Cancer Survivors' Quality of Life

Among the recent papers associated with Tami Pilot-Matias are:

  • "Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials" (2020) published in Journal of Hepatology
  • "Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study" (2020) published in The Lancet. Gastroenterology & Hepatology
  • "Burden of nonalcoholic fatty liver disease in Canada, 2019-2030: a modelling study" (2020) published in CMAJ Open
  • "Effectiveness and Renal Safety of Tenofovir Alafenamide Fumarate among Chronic Hepatitis B Patients: Real-World Study" (2021) published in Journal of Viral Hepatitis
  • "Reduced immune responses to hepatitis B primary vaccination in obese individuals with nonalcoholic fatty liver disease (NAFLD)" (2021) published in npj Vaccines

Frequent co-authors in the scientist's research output include:

  • Alnoor Ramji
  • Hin Hin Ko
  • Scott Fung
  • Curtis Cooper
  • Carla S. Coffin

The publications appear regularly in specific academic venues such as:

  • Journal of Hepatology
  • Canadian Liver Journal
  • The American Journal of Gastroenterology
  • Gastroenterology
  • The Lancet. Gastroenterology & Hepatology

Best Publications

  • ISOLATION OF NOVEL VIRUS-LIKE SEQUENCES ASSOCIATED WITH HUMAN HEPATITIS

    J N Simons;T P Leary;G J Dawson;T J Pilot-Matias

  • Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.

    Jordan J. Feld;Kris V. Kowdley;Eoin Coakley;Samuel Sigal

  • Identification of two flavivirus-like genomes in the GB hepatitis agent.

    J N Simons;T J Pilot-Matias;T P Leary;G J Dawson

  • Sequence and genomic organization of GBV‐C: A novel member of the flaviviridae associated with human non‐A‐E hepatitis

    Leary Tp;Muerhoff As;Simons Jn;Pilot-Matias Tj

  • Molecular and biophysical characterization of TT virus: Evidence for a new virus family infecting humans

    Mushahwar Ik;Erker Jc;Muerhoff As;Leary Tp

  • Glecaprevir–Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection

    Stefan Zeuzem;Graham R Foster;Stanley Wang;Armen Asatryan

  • An Interferon-free Antiviral Regimen for HCV after Liver Transplantation

    Paul Y. Kwo;Parvez S. Mantry;Eoin Coakley;Helen S. Te

  • Exploratory study of oral combination antiviral therapy for hepatitis C

    Fred Poordad;Eric Lawitz;Kris V. Kowdley;Daniel E. Cohen

  • Ombitasvir, Paritaprevir Co-dosed With Ritonavir, Dasabuvir, and Ribavirin for Hepatitis C in Patients Co-infected With HIV-1: A Randomized Trial

    Mark S. Sulkowski;Joseph J. Eron;David Wyles;Roger Trinh

  • Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial

    Christophe Hézode;Tarik Asselah;K Rajender Reddy;Tarek Hassanein

  • Genomic organization of GB viruses A and B: two new members of the Flaviviridae associated with GB agent hepatitis.

    A S Muerhoff;T P Leary;J N Simons;T J Pilot-Matias

  • Phase 2b Trial of Interferon-free Therapy for Hepatitis C Virus Genotype 1

    Kris V. Kowdley;Eric Lawitz;Fred Poordad;Daniel E. Cohen

  • Hepatitis C virus drug resistance–associated substitutions: State of the art summary

    Erik Lontok;Patrick Harrington;Anita Howe;Tara Kieffer

  • Mutations Conferring Resistance to a Potent Hepatitis C Virus Serine Protease Inhibitor In Vitro

    Liangjun Lu;Tami J. Pilot-Matias;Kent D. Stewart;John T. Randolph

  • Molecular and serologic analysis in the transmission of the GB hepatitis agents

    G G Schaluder;G J Dawson;J N Simons;T J Pilot-Matias

  • Prevalence studies of GB virus-C infection using reverse transcriptase-polymerase chain reaction.

    George J. Dawson;George G. Schlauder;Tami J. Pilot-Matias;Dwain L Thiele

  • Sequence heterogeneity within the 5′-terminal region of the hepatitis GB virus C genome and evidence for genotypes

    A.Scott Muerhoff;John N. Simons;Thomas P. Leary;James C. Erker

  • Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.

    Hiromitsu Kumada;Kazuaki Chayama;Lino Rodrigues;Fumitaka Suzuki

  • Identification of host genes involved in hepatitis C virus replication by small interfering RNA technology

    Teresa I. Ng;Hongmei Mo;Tami Pilot-Matias;Yupeng He

  • In Vitro and In Vivo Antiviral Activity and Resistance Profile of Ombitasvir, an Inhibitor of Hepatitis C Virus NS5A

    Preethi Krishnan;Jill Beyer;Neeta Mistry;Gennadiy Koev

  • Glecaprevir/pibrentasvir for hepatitis C virus genotype 3 patients with cirrhosis and/or prior treatment experience: A partially randomized phase 3 clinical trial.

    David Wyles;Fred Poordad;Stanley Wang;Laurent Alric

Frequent Co-Authors

Isa K. Mushahwar
Isa K. Mushahwar Abbott (United Kingdom)
Christophe Hézode
Christophe Hézode Université Paris Cité
Hiromitsu Kumada
Hiromitsu Kumada Fukuoka University
Kazuaki Chayama
Kazuaki Chayama Hiroshima University
Stanislas Pol
Stanislas Pol Université Paris Cité
Graham R. Foster
Graham R. Foster Queen Mary University of London
Hongmei Mo
Hongmei Mo Gilead Sciences (United States)
Fumitaka Suzuki
Fumitaka Suzuki Toranomon Hospital
Tarik Asselah
Tarik Asselah Université Paris Cité
Kris V. Kowdley
Kris V. Kowdley Washington State University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring related online degrees can open a range of opportunities for those interested in Microbiology and allied fields. For example, many students opt for an online public health masters programs easy to get into to expand their expertise in epidemiology and global health, often complementing their science background.

Certification is another critical step in career advancement. Those drawn to pediatric care might consider the ccls certification, which prepares professionals to support children’s emotional well-being during medical procedures. This diverse credential can offer fulfilling job prospects beyond traditional lab roles.

For individuals with unique circumstances, there are inclusive opportunities as well. Several online colleges that accept felons provide pathways to education and professional development, making it clear that a past record does not have to hinder a promising career in science or healthcare.

Lastly, an emerging field combining healthcare and holistic practices is functional medicine nursing. Becoming a functional medicine np offers specialized training that integrates traditional biology with natural treatments, suitable for those passionate about innovative patient care.

Best Scientists Citing Tami Pilot-Matias

Trending Scientists